Prasugrel PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Prasugrel PCD pharma franchise company offering 2 Prasugrel formulations across Tablets. Every batch is manufactured in DCGI-approved, WHO-GMP compliant facilities and supplied to franchise partners on a monopoly basis with full promotional backing.

What is Prasugrel?

Prasugrel is a third-generation thienopyridine antiplatelet agent. It is a prodrug whose active metabolite irreversibly binds the P2Y12 subtype of the platelet ADP receptor, preventing ADP-mediated platelet activation and aggregation. Compared with clopidogrel it produces faster and more consistent platelet inhibition, because its metabolic activation is less dependent on CYP2C19 genotype. It is used in acute coronary syndrome managed with percutaneous coronary intervention. See the compound record on PubChem.

Prasugrel Range Available for Franchise

Our Prasugrel portfolio comprises 2 formulations available in the following dosage forms: Tablets. Brand names, compositions, packing and net rates are shared on request with partners holding a valid Drug License. Contact us for the current Prasugrel price list and stock position.

Therapeutic Applications of Prasugrel

Prasugrel is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome — unstable angina, NSTEMI and STEMI — who are undergoing percutaneous coronary intervention, generally as dual antiplatelet therapy with aspirin. It is prescribed by interventional cardiologists and cardiologists, and continued under consulting physicians. It carries a significant bleeding risk and is contraindicated in patients with prior stroke or TIA; it is strictly a prescription-only, specialist-initiated medicine.

Why Prasugrel is a High-Potential Molecule for Distributors

Prasugrel's commercial case is tied directly to India's rising volume of coronary interventions. Every angioplasty and stent procedure is followed by twelve months of mandatory dual antiplatelet therapy — the patient cannot stop without risking stent thrombosis — so a single stenting event locks in a year of guaranteed monthly refills. Prasugrel is increasingly favoured over clopidogrel in the post-PCI setting because its effect does not depend on CYP2C19 metabolism, an advantage cardiologists actively look for. As catheterisation labs proliferate in tier-2 cities, the prescriber base widens well beyond metro hospitals.

Why Choose Cafoli Lifecare for Your Prasugrel Franchise

Cafoli Lifecare works with over 1000+ franchise partners across India. Partners receive monopoly rights for their district or territory, WHO-GMP certified and DCGI-approved products, complete promotional inputs (visual aids, MR bags, samples, prescription pads, gifts), transparent net rates, and dependable dispatch. Our documentation and stock support are built for distributors who want to scale without operational friction.

References

1. PubChem — Prasugrel compound record (NIH / NCBI)
2. MedlinePlus — Prasugrel drug information (US National Library of Medicine)
3. PubMed — clinical literature on Prasugrel